Results 161 to 170 of about 17,718 (201)

Retreatment and Reactivation Rates Following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Alghamdi A, Alasmari F, Aletani T, Ezzi S, Alharbi S, Alasmari TF, Alalgum H, Bin Sawad M, Talaat K.   +8 more
europepmc   +1 more source

Anti-VEGF treatment switch in real-world DME patients: ranibizumab versus aflibercept for bevacizumab DME non-responding patients (SWIRL study). [PDF]

BMJ Open Ophthalmol
Lim LW, Choy D, Song WJ, Ngo WK, Thng ZX, Mi HF, Soh YQ, Lilian K, Chin JYH, Chia KJW, Laude A, Tan CS, Lim TH, Too I, Gan NY, Rajagopalan R.   +15 more
europepmc   +1 more source

Perception of pain during intravitreal injections: a clinical trial on the effect of entry site distance from the limbus on perceived pain. [PDF]

Int J Retina Vitreous
Fan J, Guiseppi R, Digbeu B, Banaee T.
europepmc   +1 more source

Blood Pressure Status Modulates the Therapeutic Response to Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Macular Edema: A Post Hoc Subgroup Analysis of the COMET Trial. [PDF]

J Diabetes
Ishibashi R, Koshizaka M, Takatsuna Y, Tatsumi T, Baba T, Yamamoto S, Yokote K.   +6 more
europepmc   +1 more source

Biometric analysis of disc-fovea distance and optic disc diameter in premature infants using wide-field fundus imaging. [PDF]

Sci Rep
Kwak J, Son NH, Bang SP, Jang JH.
europepmc   +1 more source

Ranibizumab induces regression of diabetic retinopathy (DR) in more than three-quarters of patients with high-risk non-proliferative diabetic retinopathy (NPDR) independent of retinal nonperfusion

, 2016
Charles C. Wykoff, Shamika Gune, Lauren Hill, Miranda Hemphill, Zdenka Hašková   +4 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ranibizumab

Drugs, 2007
Ranibizumab is the antigen-binding fragment of a recombinant, humanised monoclonal antibody, which binds with high affinity to, and inhibits the activity of, all active forms of vascular endothelial growth factor A, an important mediator in the development of choroidal neovascularisation.
Stephanie K A, Blick, Gillian M, Keating, Antona J, Wagstaff   +2 more
  +5 more sources

Ranibizumab

Reactions Weekly, 2023
  +8 more sources

Ranibizumab

Practical Diabetes, 2013
Stephen Burgess, Gerry McKay, Miles Fisher   +2 more
  +4 more sources